Brickell Biotech Inc (OQ:BBI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5777 Central Ave Ste 102
BOULDER CO 80301-2870
Tel: N/A
Website: www.vical.com
IR: See website
<
Key People
Reginald L. Hardy
Chairman of the Board, Co-Founder
Robert B. Brown
Chief Executive Officer, Director
Andrew D. Sklawer
Co-Founder, Chief Operating Officer, Secretary
R. Michael Carruthers
Chief Financial Officer
Jose Breton
Chief Accounting Officer, Controller
David R. McAvoy
Chief Compliance Officer, General Counsel, Assistant Secretary
Deepak Chadha
Chief Research and Development Officer
Adam Scott Levy
Chief Business Officer
 
Business Overview
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company's pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company's product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
Financial Overview
For the nine months ended 30 September 2019, Brickell Biotech Inc revenues increased from $1.5M to $7.2M. Net loss applicable to common stockholders decreased 78% to $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$4.06 to -$0.67.
Employees: 30 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $7.37M as of Sep 30, 2019
EBITDA (TTM): -$15.74M as of Sep 30, 2019
Net annual income (TTM): -$6.35M as of Sep 30, 2019
Free cash flow (TTM): -$24.53M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 7,810,680 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization